Jan Weiler

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 14)

Average Co-Inventor Count = 7.3

ph-index = 4

Forward Citations = 56(Granted Patents)

Location History:

Lorrach-Haagen, DE (2012 - 2019)
Newton, MA (US) (2019 - 2022)
Cambridge, MA (US) (2018 - 2023)

Company Filing History:

Arrowhead Pharmaceuticals, Inc.

patents

2 out of 2,595

University of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 2012-2023

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11578130 - Regulatable chimeric antigen receptor (2023-02-14),

2. 11473083 - Compositions and methods for decreasing tau expression (2022-10-18),

3. 11261444 - Organic compositions to treat EPAS1-related diseases (2022-03-01),

4. 11066667 - Organic compositions to treat APOC3-related diseases (2021-07-20),

5. 11008570 - 3' end caps for RNAi agents for use in RNA interference (2021-05-18),

6. 10538765 - Organic compositions to treat EPAS1-related diseases (2020-01-21),

7. 10519446 - Organic compounds to treat hepatitis B virus (2019-12-31),

8. 10329563 - Organic compositions to treat HSF1-related diseases (2019-06-25),

9. 10287354 - Regulatable chimeric antigen receptor (2019-05-14),

10. 10240153 - Organic compositions to treat APOC3-related diseases (2019-03-26),

11. 10227588 - 3'end caps for RNAi agents for use in RNA interference (2019-03-12),

12. 10023862 - Organic compositions to treat beta-catenin-related diseases (2018-07-17),

13. 9988627 - Formats for organic compounds for use in RNA interference (2018-06-05),

14. 9868949 - Organic compositions to treat EPAS1-related diseases (2018-01-16),

15. 8097716 - Interfering RNA duplex having blunt-ends and 3'-modifications (2012-01-17),

Title: Innovator Spotlight: Jan Weiler - Pioneering Advances in Immunotherapy and Neurological Disorders

Introduction:

Jan Weiler, a brilliant inventor based in Cambridge, MA, has made significant contributions to the fields of immunotherapy and neurological disorders. With an impressive portfolio of 15 patents, his groundbreaking work has the potential to revolutionize the way we approach disease treatment.

Latest Patents:

Jan Weiler's latest patents showcase his expertise in developing cutting-edge medical technologies. One of his notable inventions is the Regulatable Chimeric Antigen Receptor (RCAR), which allows for the precise control of intracellular signaling and proliferation in RCAR-expressing cells. This innovation promises to enhance the effectiveness of immune responses, particularly in the treatment of various diseases.

Another remarkable patent by Jan Weiler focuses on Compositions and Methods for Decreasing Tau Expression. By targeting tau mRNA and protein expression, these compositions offer new avenues for treating tau-related diseases and disorders, potentially offering hope to countless patients worldwide.

Career Highlights:

Throughout his career, Jan Weiler has made significant contributions to several renowned companies, including Novartis AG and Arrowhead Pharmaceuticals, Inc. His innovative spirit and dedication to scientific advancement have earned him recognition as a leading figure in the field of biotechnology.

Collaborations:

Jan Weiler has had the privilege of collaborating with esteemed professionals in the industry, including Dieter Huesken and Jeremy Lee Baryza. Together, they have worked on cutting-edge projects that have pushed the boundaries of innovation in medicine and healthcare.

Conclusion:

In conclusion, Jan Weiler stands out as a visionary inventor who is shaping the future of healthcare through his groundbreaking research and inventions. His commitment to advancing science and improving patient outcomes is truly commendable, and his work continues to inspire and drive progress in the fields of immunotherapy and neurology.

This text is generated by artificial intelligence and may not be accurate.